Last reviewed · How we verify
STP938
At a glance
| Generic name | STP938 |
|---|---|
| Sponsor | Step Pharma, SAS |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase 1 Study to Assess STP938 as a Monotherapy in Adults With High Risk Essential Thrombocythaemia (PHASE1)
- A Phase 1/2 Study of STP938 for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas (PHASE1, PHASE2)
- Study of STP938 in Advanced Solid Tumours (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- STP938 CI brief — competitive landscape report
- STP938 updates RSS · CI watch RSS
- Step Pharma, SAS portfolio CI